Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Kevin Shianna, Joel Jung, Tuuli Lappalainen, Joe Pickrell, Francisco De La Vega


Illumina has hired Kevin Shianna as a sequencing specialist. Previously he was deputy scientific director of sequencing operations at the New York Genome Center. Prior to joining the NYGC he was at Duke University Medical Center where he was most recently an assistant professor and director of operations of the Center for Human Genome Variation.

BioNano Genomics has appointed Joel Jung as chief financial officer. Previously, he was CFO of Agraquest and was also CFO and treasurer of Celera. He holds an MBA in finance from the University of California, Berkeley and a BS in aeronautical and astronautical engineering from Purdue University.

Tuuli Lappalainen and Joe Pickrell have joined the New York Genome Center as junior investigators and core members.

Lappalainen holds a joint appointment as an assistant professor in the department of systems biology at Columbia University. She holds a PhD in genetics from the University of Helsinki and did postdoctoral research at the University of Geneva and Stanford University.

Pickrell is an adjunct professor in the department of biological sciences at Columbia University and was previously a postdoctoral research at Harvard Medical School. He holds a PhD in human genetics from the University of Chicago and a BS in biology from the University of North Carolina, Chapel Hill.

Annai Systems has appointed Francisco De La Vega to be chief scientific officer, a new position at the company.

De La Vega formerly was vice president of genome science at Real Time Genomics, and he spent 13 years at Applied Biosystems, where he was the distinguished scientific fellow and vice president of next-generation sequencing applications. He also has worked in sequencing community projects such as the 1000 Genomes Project and the Genome-in-a-Bottle Consortium.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.